Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.
1. A method for reducing angiogenesis in a subject in need thereof comprising, administering to the subject a composition comprising: a pulverized or ground amniotic membrane preparation prepared from placenta that is frozen or previously frozen, wherein angiogenesis is reduced.
2. The method of claim 1 , wherein the composition is formulated as a non-solid dosage form.
3. The method of claim 1 , wherein the composition is formulated as a solution, drops, suspension, aerosol, paste, spray, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, shampoo, or combination thereof.
4. The method of claim 1 , wherein the composition is formulated for ophthalmic administration.
5. The method of claim 4 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjunctival injection, retrobulbar injection, intracameral injection, sub-Tenon's injection, ocular implantation or ocular insertion.
6. The method of claim 1 , wherein the composition is for topical administration.
7. The method of claim 1 , wherein the composition further comprises a penetration enhancer and an aqueous adjuvant.
8. The method of claim 1 , wherein the composition is for systemic administration.
9. The method of claim 1 , wherein the composition is formulated as a solid dosage form.
10. The method of claim 1 , wherein the composition is formulated as a solid dosage form, and wherein the solid dosage form is for inserting between an eye and an eyelid, or in a conjunctival sac.
11. The method of claim 1 , wherein the composition is formulated as a solid oral dosage form.
12. The method of claim 1 , wherein the composition is formulated as a capsule or tablet.
13. The method of claim 1 , wherein the composition is formulated for controlled release.
14. The method of claim 1 , wherein the composition is formulated as an enteric coated oral dosage form.
15. The method of claim 1 , wherein the amniotic membrane (AM) preparation comprises high molecular weight hyaluronan (HA) that is cross-linked by a covalent bond to the heavy chain of inter-α-trypsin inhibitor (IαI), the high molecular weight HA having a molecular weight greater than 1000 kDa.
16. The method of claim 1 , wherein the amniotic membrane (AM) preparation comprises tumor necrosis factor-stimulated gene 6 (TSG-6).
17. The method of claim 1 , wherein the composition is a pharmaceutical composition and further comprises a pharmaceutically acceptable excipient.